BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8862724)

  • 1. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
    Hasinoff BB; Yalowich JC; Ling Y; Buss JL
    Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
    Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
    Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
    Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
    Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.
    Malisza KL; Hasinoff BB
    Free Radic Biol Med; 1996; 20(7):905-14. PubMed ID: 8743977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
    Langer SW; Sehested M; Jensen PB
    Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
    Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
    Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
    Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
    Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Wu X; Yang Y
    J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
    Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
    Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane (ICRF-187).
    Weiss G; Loyevsky M; Gordeuk VR
    Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
    Sargent JM; Williamson CJ; Yardley C; Taylor CG; Hellmann K
    Br J Cancer; 2001 Apr; 84(7):959-64. PubMed ID: 11286477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.